Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

that prevent cell-to-cell transmission of virus down the respiratory tract, potentially reducing the severity of influenza disease; and cell mediated immune responses to M1 may lead to destruction of cells already infected. Further, the vaccine is made in cell culture rather than eggs, which permits an exact genetic match to the flu strains causing illness since there is no requirement for adapting the vaccine to grow in eggs.

"We are pleased to complete enrollment so quickly of our seasonal influenza vaccine Phase IIa trial", said Dr. Rahul Singhvi, President and CEO of Novavax. "The completion of enrollment for this critical clinical trial within a week of its initiation should enable us to release top line data from this study in the fourth quarter of this year. I congratulate our team on this accomplishment and for advancing two novel influenza vaccines into Phase II development this year."

Novavax's novel manufacturing approach

Novavax's manufacturing process makes it possible to rapidly produce a vaccine that contains strains that are an exact genetic match to the strains circulating in the community causing influenza disease. Novavax's influenza VLPs are produced through recombinant technology in insect cell culture, utilizing a manufacturing process that will consist entirely of disposable, ready-to-use equipment. Current yields are 7 to 10 times higher than those of traditional egg-based or mammalian cell culture manufacturing. Because the Novavax process involves recombinant technology and does not require a live influenza virus, a matched vaccine for the first seasonal influenza clinical trial was manufactured within 12 weeks of identification of the Centers for Disease Control and Prevention ("CDC") released seasonal strains, or approximately half the time required to manufacture egg-based vaccines. The ability to rapidly respond to the identification of annual seasonal strains may be important in providing timely vaccine in advance
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ... revenue and share analysis. , Full Copy ...
(Date:12/24/2014)... Long Island, New York (PRWEB) December 23, 2014 ... , and the Long Island Affiliate of ITRA Global, the ... economy’s slow but steady recovery. This is evidenced by ... and the strong stock market. Low energy costs have ... low. The only negative is the housing market remaining ...
(Date:12/24/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China ... plasma-based biopharmaceutical company in China ... Taibang Biological Products Co. Ltd., has received Good ... and Drug Administration (the "CFDA") for its new ... the Company,s public filings, the CFDA inspected this ...
(Date:12/24/2014)... YORK , Dec. 23, 2014  NeuroLifeSciences announced ... mazindol in children with attention deficit/hyperactivity disorder published in ... . The paper, titled "Pilot Phase ... disorder" ( Konofal et al, Drug Des ... ) shows that mazindol might be an effective, ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... 26 Lexicon,Pharmaceuticals, Inc. (Nasdaq: LXRX ) today ... at the Piper Jaffray 19th Annual,Health Care Conference at ... November 28, 2007 at 8:30 a.m. Eastern Time., ... on Lexicon,s,corporate website at http://www.lexpharma.com . An archived ...
... Income up $1,036,024, or 89%, for the nine months ended September 30, ... ... China, Nov. 26 /Xinhua-PRNewswire-FirstCall/ -- China Kangtai,Cactus Bio-tech Inc. (OTC Bulletin Board: ... cactus-based,consumer products, filed its quarterly report on SEC Form 10QSB on November,19, ...
... 26 PRA International,(Nasdaq: PRAI ), a ... Chambers has been named its senior vice president ... to human resources that will,help PRA grow," said ... and employment law in addition to strong tactical ...
Cached Biology Technology:Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 2China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 3China Kangtai Cactus Biotech, Inc. Reports Third Quarter 2007 Financial Results 4Chambers Joins PRA International as Senior Vice President of Human Resources 2
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:11/21/2014)... According to a new market research report ... Control, Intrusion Detection, Parking Management, Under Vehicle Inspection), End ... - Global Forecasts to 2020", published by MarketsandMarkets, The ... $25 Billion in 2014 and is expected to reach ... 8.69%. Browse 116 market data Tables and ...
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... Disorders and Stroke (NINDS), a component of the National Institutes ... the Morris K. Udall Centers of Excellence in Parkinson,s Disease ... totaling more than $16 million for Emory University in Atlanta ... NINDS Director Story Landis, Ph.D., announced the ...
... the future" story, scientists today reported that the sustainable, ... ago is re-emerging as a "green" alternative to wood ... the American Chemical Society, they described development of new ... and tofu and could mean a new generation of ...
... increase of up to 4.2 C and the end ... targets are not revised in the Copenhagen Accord, the international ... change conference. Just ahead of the next ... in Tianjin, China, a new report published today, Wednesday, 29 ...
Cached Biology News:NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3Climate accord loopholes could spell 4.2-degree rise in temperature and end of coral reefs by 2100 2
... This kit #27295 has improved stability and convenience ... kit not only has overcome this problem but ... we have changed the formulation of HRP conjugated ... 1). By this change, the stability of the ...
Mouse monoclonal [BC-4] to Aggrecan xxPEN ( Abpromise for all tested applications). entrezGeneID: 176 SwissProtID: P16112...
... screening, low melting point agarose where separation ... recommended for separation of nucleic acids less ... products. Micro ABgarose is also suited to ... blotting techniques. At a 3% concentration, Micro ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Biology Products: